Drug intelligence / Profile preview

Spritz-OM

Development stage: Unknown
Lead developer: OtoMedicine
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intranasal

Overview

Spritz-OM is a novel live biotherapeutic product developed as a probiotic nasal spray to prevent childhood middle ear infections (otitis media). Developed by Oto Medicines, a spin-out from The Kids Research Institute Australia, the therapy consists of healthy bacteria designed to be delivered intranasally. Its mechanism of action involves the competitive inhibition of major bacterial pathogens responsible for over 50% of ear infections, effectively outcompeting them to prevent the onset of infection. The product aims to reduce the global reliance on antibiotics and surgical interventions for recurrent or chronic otitis media. As of 2025, the program is entering Phase 1 clinical trials.

Brand names: Spritz-OM

Beyond the preview

Go deeper on Spritz-OM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spritz-OM.

Explore the full profile